パーキンソン病(PD)患者を対象としたブンタネタップの研究
パーキンソン病の参加者を対象としたBuntanetap治療の長期安全性を調査するオープンラベル臨床試験
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
調査の概要
詳細な説明
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Sarah MacCallum, BSN RN
- 電話番号:484-875-3192
- メール:maccallum@annovisbio.com
研究連絡先のバックアップ
- 名前:Alexander Morin, PhD
- メール:morin@annovisbio.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 募集
- University of Alabama at Birmingham
-
コンタクト:
- Candace Cromer
- 電話番号:205-996-4034
- メール:candacecromer@uabmc.edu
-
主任研究者:
- Natividad Stover, M.D.
-
-
Arizona
-
Sun City、Arizona、アメリカ、85351
- 募集
- Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
-
主任研究者:
- Sara Dhanani, M.D.
-
コンタクト:
- Serena Lowery
- 電話番号:623-832-6500
- メール:serena.lowery@bannerhealth.com
-
-
California
-
Fountain Valley、California、アメリカ、92708
- 募集
- Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
-
主任研究者:
- Daniel Truong, M.D.
-
コンタクト:
- Evan Moreno-Davis
- 電話番号:714-378-5074
- メール:evan@pmdi.org
-
-
Colorado
-
Englewood、Colorado、アメリカ、80113
- 募集
- Cenexel Rocky Mountain Clinical Research
-
コンタクト:
- Sally Modzelewski
- 電話番号:720-776-0092
- メール:s.modzelewski@cenexel.com
-
主任研究者:
- Meagen Salinas, M.D.
-
-
Connecticut
-
Stamford、Connecticut、アメリカ、06824
- 募集
- New England Institute for Clinical Research (Ki Health Partners)
-
コンタクト:
- Valerija Misev
- 電話番号:125 203-914-1903
- メール:Valerija@neinh.com
-
主任研究者:
- Peter McAllister, M.D.
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- 募集
- First Choice Neurology - Aventura Neurologic Associates
-
主任研究者:
- Jonathan Cross, M.D.
-
コンタクト:
- Jonathan Palmquist
- 電話番号:786-744-5596
- メール:jpalmquist@vintrials.com
-
Daytona Beach、Florida、アメリカ、32117
- 募集
- Arrow Clinical Trials
-
コンタクト:
- Vinoothna Moluguri
- 電話番号:386-316-6152
- メール:vmoluguri@arrowtrials.com
-
主任研究者:
- David Billmeier, M.D.
-
DeLand、Florida、アメリカ、32720
- 募集
- Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
-
主任研究者:
- Bruce Rankin, D.O.
-
コンタクト:
- Erica Santoni
- 電話番号:4608 1-386-785-2400
- メール:erica.santoni@accelclinical.com
-
Miami、Florida、アメリカ、33172
- 募集
- Professional Research Center
-
コンタクト:
- Saylet Corbera
- 電話番号:786-359-4091
- メール:RamirezMD@professionalresearchcenter.com
-
Miami、Florida、アメリカ、33015
- まだ募集していません
- Ezy Medical Research Co.
-
コンタクト:
- Priscilla Hernandez
- 電話番号:786-483-8162
- メール:phernandez@ezytrials.com
-
Ocala、Florida、アメリカ、34470
- 募集
- Renstar Medical Research
-
主任研究者:
- Annette Nieves, M.D.
-
コンタクト:
- Sebastian Mesa
- 電話番号:352-629-5800
- メール:sebastian.mesa@renstar.net
-
Tampa、Florida、アメリカ、33613
- 募集
- University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
-
コンタクト:
- Erica Botting
- 電話番号:813-974-8026
- メール:ericabotting@usf.edu
-
主任研究者:
- Robert Hauser, M.D., MBA
-
Winter Park、Florida、アメリカ、32789
- 募集
- Conquest Research
-
コンタクト:
- Fabiola Perez
- 電話番号:407-916-0060
- メール:fabiola.perez@conquestresearch.com
-
主任研究者:
- Rekha Gandhi, M.D.
-
-
Georgia
-
Decatur、Georgia、アメリカ、30030
- 募集
- iResearch Atlanta
-
コンタクト:
- Elizabeth Davis
- 電話番号:404-537-1281
- メール:e.davis@cenexel.com
-
主任研究者:
- Kimball Johnson, M.D.
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46256
- 募集
- Josephson Wallack Munshower Neurology, P.C.
-
主任研究者:
- Kristi George, M.D.
-
コンタクト:
- Tammy Root
- 電話番号:1-317-573-6061
- メール:troot@jwmneuro.com
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
-
コンタクト:
- Kelly Lyons
- 電話番号:913-588-7159
- メール:klyons@kumc.edu
-
主任研究者:
- Rajesh Pahwa, M.D.
-
-
Michigan
-
Farmington Hills、Michigan、アメリカ、48334
- 募集
- Quest Research Institute
-
主任研究者:
- Aaron Ellenbogen, D.O.
-
コンタクト:
- Savannah Carra
- 電話番号:248-957-8940
- メール:savannah.carra@questri.com
-
-
New York
-
New York、New York、アメリカ、10019
- 募集
- Mount Sinai Hospital
-
主任研究者:
- Joohi Jimenez-Shahed, M.D.
-
コンタクト:
- Sofya Glazman
- 電話番号:646-493-1862
- メール:sofya.glazman@mountsinai.org
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke Department of Neurosurgery
-
主任研究者:
- Kyle Mitchell, M.D.
-
コンタクト:
- Vera George
- 電話番号:919-668-3885
- メール:vera.george@duke.edu
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University Wexner Medical Center
-
主任研究者:
- Zachary Jordan, M.D.
-
コンタクト:
- Victoria Miller
- 電話番号:614-688-8672
- メール:victoria.miller@osumc.edu
-
-
Oklahoma
-
Tulsa、Oklahoma、アメリカ、74136
- 募集
- The Movement Disorder Clinic of Oklahoma
-
コンタクト:
- Elise Gibson
- 電話番号:918-392-4530
- メール:mdcclinicaltrials@gmail.com
-
主任研究者:
- Kevin Klos, M.D.
-
-
Pennsylvania
-
Willow Grove、Pennsylvania、アメリカ、19090
- 募集
- Abington Neurology
-
主任研究者:
- David Weisman, M.D.
-
コンタクト:
- Brian Weingartner
- 電話番号:130 215-957-9250
- メール:brian.weingartner.ana@gmail.com
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29401
- 募集
- Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
-
コンタクト:
- Sandra Wilson
- 電話番号:843-792-3223
- メール:wilsosan@musc.edu
-
主任研究者:
- Vanessa Hinson, M.D., PhD
-
-
Tennessee
-
Cordova、Tennessee、アメリカ、38018
- 募集
- Neurology Clinic, P.C.
-
コンタクト:
- Ye Liu
- 電話番号:901-747-1111
- メール:yliu@neuroclinic.org
-
主任研究者:
- Kendrick Henderson, M.D.
-
Memphis、Tennessee、アメリカ、38157
- 募集
- Veracity Neuroscience LLC
-
コンタクト:
- Hannah Touliatos
- 電話番号:901-604-0345
- メール:hannah@veracityneuroscience.com
-
主任研究者:
- Mark LeDoux, M.D., PhD
-
-
Texas
-
Round Rock、Texas、アメリカ、78681
- 募集
- Central Texas Neurology
-
コンタクト:
- Koni Lopez
- 電話番号:512-218-1222
- メール:k.lopez@ctncpa.org
-
主任研究者:
- Elizabeth Peckham, M.D.
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- 募集
- University of Virginia Health System (UVAHS) - Adult Neurology Clinic
-
主任研究者:
- Binit Shah, M.D.
-
コンタクト:
- Lauren Miller
- 電話番号:434-982-6599
- メール:fdk5dn@uvahealth.org
-
-
Washington
-
Spokane、Washington、アメリカ、99202
- 募集
- Inland Northwest Research
-
主任研究者:
- Jason Aldred, M.D.
-
コンタクト:
- Aaron Dahl
- 電話番号:509-960-2818
- メール:adahl@inwresearch.com
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Medical College of Wisconsin
-
コンタクト:
- Shelby Schold
- 電話番号:414-955-0698
- メール:sschold@mcw.edu
-
主任研究者:
- Karen Blindauer, M.D.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and
a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.
b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.
i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.
-
Have a support person who will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
- Standard of care anti-parkinsonian medication,
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
- Mood-stabilizing psychotropic agents including, but not limited to, lithium,
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Good general health with no disease expected to interfere with the study.
Exclusion Criteria:
-
Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).
-
A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.
-
Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54
-
Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.
-
Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).
-
Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
A learning disability or developmental delay.
-
Participants whom the site PI deems to be otherwise ineligible.
-
A known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified microcrystalline cellulose
- Dibasic calcium phosphate dihydrate
- Mannitol
- Stearic acid
- Hypromellose (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Is currently pregnant, breast-feeding, and/or lactating.
-
Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1 - buntanetap
Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun |
buntanetap capsules 30 mg by mouth daily |
|
実験的:Cohort 2 - buntanetap
Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. |
buntanetap capsules 30 mg by mouth daily |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety of buntanetap
時間枠:36-months of treatment
|
Safety assessments of participants with PD receiving treatment with buntanetap |
36-months of treatment
|
|
Adverse Events (AE)
時間枠:36-months of treatment
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention |
36-months of treatment
|
|
Treatment Emergent Adverse Events (TEAE)
時間枠:36-months of treatment
|
TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state |
36-months of treatment
|
|
Serious Adverse Events (SAE)
時間枠:36-months of treatment
|
SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly |
36-months of treatment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Laurie Sanders, Ph.D.、Duke Clinical Research Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。